Read Recent Press Releases

23 Mar 2009 9 Days to Go until BioTrinity - Choice of Ten Expert Workshops
18 Mar 2009 Partnering surges at BioTrinity 2009 - just 10 working days left to register
11 Mar 2009 Do you know which 35 investors are partnering at BioTrinity 2009?
03 Mar 2009 Record Registrations - Only Four Weeks Left to Register (Partnering is Live)
23 Feb 2009 $32bn Under Management - Meet Life Science VCs at BioTrinity 2009
10 Feb 2009 Key Industry Issues Dealt with at BioTrinity 2009
02 Feb 2009 BioTrinity 2009 - Preliminary Programme Released
01 Dec 2008   Innovators and 2008 Fundraisers Featured Among Presenters at BioTrinity 2009
04 Sep 2008    Hold the Date for BioTrinity 2009: UK's Premier Biotechnology and Investment conference - early registration opens
09 Apr 2008    BioTrinity 2008 Oxford: 55 hours left to register online - partnering activity surges
03 April 2008   Exciting new VC firm to take part in Panel Discussion at BioTrinity 2008
18 Mar 2008   Oxford BioMedica develops strategic development plan with the commercialisation of TroVax
6 Mar 2008   Financing Alternatives for Biotechs Will be a Key Feature on the Programme: Over 300 Companies Expected at BioTrinity 2008 - Oxford
27 Feb 2008   Over 140 Companies Now Registered for BioTrinity 2008
8 Feb 2008   Biotech Advances in the Spotlight at BioTrinity 2008
22 Jan 2008   Announcing BioTrinity 2008 and the Billion Euro BioCluster
19 Nov 2007   BioTrinity Registration Opens - Oxford Biotech Investment Remains Buoyant Despite Market Turbulence
16 Apr 2007   BioTrinity Marks the Resurgence of the Oxford and South East Biotech Industry
31 Jan 2007   Innovative Business Development Models and Deal Structures to be Discussed at BioTrinity 2007: Background to Eli Lilly Prosidion Licensing Deal Presented as Case Study (Word version)
15 March 2007   Dr Andy Richards, Serial Biotech Entrepreneur, to give pre-conference reception speech at BioTrinity
14 Feb 2007   Europe's Largest Life Science Fund to take part in BioTrinity 2007: Panel to Discuss How to Attract Globally Focussed Investment (Word version)
25 Jan 2007   With two months left before BioTrinity 2007 - is your company's name still missing from the list of over 100 companies already registered?
21 Dec 2006   Announcement of Preliminary Programme for BioTrinity 2007
13 Dec 2006   Stem Cell Therapy in Humans: The challenges and benefits to be discussed at BioTrinity 2007
2 Nov 2006   Introducing BioTrinity 2007 - The South East's equivalent of Genesis and the ERBI Bioexchange

Articles in the Press mentioning BioTrinity 2007

A Capital Adventure Oxford Times "In Business", Bioline, 21st September 2007

Drug firm seeks new identity   Oxford Mail, Tuesday 27th March 2007

Cobra: 'process development is the key' Process development is the key when outsourcing clinical supply biomanufacturing to a contractor, according to an industry player.   BioPharma Reporter, 29th March 2007

Phynova - Significant progress in product pipeline   OBN, Monday 02 April 2007

US equity market potential goldmine for biotech companies. The US equity market is open to biotech companies and it is a good time for them to raise money, delegates heard at Biotrinity in Oxfordshire, UK.  10/04/2007 BioPharma Reporter.

Attracting big pharma's attention Pfizer has given an insight into what it is about smaller companies that makes the world's largest pharma company want to buy them.   Drug Researcher, 12th April 2007

Now is an ideal time for small biotechs to ink that perfect deal with big pharma, attendees heard at the recently held Biotrinity conference in Oxfordshire, UK.   BioPharma Reporter, 12th April 2007

Among our recent registrants, see who else has signed up!

VP Licensing, Shire Pharma
Principal (Life Sciences), Atlas Venture
Investment Director, Oxford Capital Partners
CEO, Solace Pharma
CEO, Glide Pharma
CEO, Chemocentryx
CEO, Celleron Therapeutics
CEO, Phynova
EVP Business Development, Evotec
CEO, Hybrid Systems
CEO, Summit plc
CEO, (OSI) Prosidion
CEO, Oxford Genome Sciences
Business Research and Development Manager, Biocompatibles